Neo-Tab Side Effects
Generic name: neomycin
Note: This document contains side effect information about neomycin. Some of the dosage forms listed on this page may not apply to the brand name Neo-Tab.
Some side effects of Neo-Tab may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to neomycin: oral solution, oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking neomycin (the active ingredient contained in Neo-Tab) hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
hearing problems, ringing in your ears, or a feeling of fullness in the ears;
spinning sensation, nausea, feeling like you might pass out;
loss of balance or coordination, trouble walking;
numbness or tingly feeling under your skin;
muscle twitching, seizure (convulsions);
urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting;
swelling, weight gain, feeling short of breath;
weak or shallow breathing; or
severe stomach cramps, diarrhea that is watery or bloody.
Less serious side effects of neomycin may include:
mild nausea, vomiting; or
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to neomycin: compounding powder, oral solution, oral tablet
Since oral neomycin (the active ingredient contained in Neo-Tab) is absorbed systemically after oral administration, its use may result in nephrotoxicity, neurotoxicity and/or ototoxicity, even at recommended doses and in patients with normal renal function.
The major renal side effect of oral neomycin (the active ingredient contained in Neo-Tab) is nephrotoxicity, which has occurred even at recommended doses and in patients with normal renal function.
Early signs of nephropathy include mild proteinuria, sloughing of renal tubular epithelial cells, formation of cellular casts, and decreases in creatinine clearance. Often there is a high output renal failure where daily urine volume may appear unchanged until significant increases in serum creatinine and BUN levels occur.
Neomycin damages renal tubules by causing tubular epithelial cell necrosis. It is considered the most nephrotoxic aminoglycoside.
Early symptoms of neomycin-induced auditory toxicity may manifest as high tone hearing loss, tinnitus, or a feeling of fullness in the ear, or its onset may be asymptomatic. If ototoxicity occurs, the onset of hearing loss is between several days to 6 weeks after therapy begins; however, it may not occur for months or years after neomycin (the active ingredient contained in Neo-Tab) has been discontinued. Symptoms of vestibulotoxicity may include tinnitus, vertigo and ataxia.
Neomycin is considered more ototoxic than vestibulotoxic. It progressively accumulates in the inner ear and which leads to sensory hair cell loss in the in the cochlea and damage to the stria vascularis. In an animal study, neomycin was found to be more ototoxic than gentamicin, kanamycin and dihydrostreptomycin.
One case report series describes 5 cases of hearing impairment associated with long-term oral neomycin therapy for hepatic encephalopathy. Doses ranged from 2 to 12 g/day and were administered for 8 to 28 months; in 2 cases paromomycin was also administered. Renal failure did not occur.
Nervous system side effects associated with oral neomycin therapy have included neuromuscular blockade, respiratory paralysis, and eighth cranial nerve damage with hearing loss, even at recommended doses and in patients with normal renal function. Symptoms of neurotoxicity include numbness, tingling, muscle twitching, and convulsions.
Oral neomycin (the active ingredient contained in Neo-Tab) therapy may result in overgrowth of nonsusceptible organisms, especially fungi.
A case of fatal Candida albicans pyelonephritis and septicemia following preoperative bowel preparation with oral neomycin and bacitracin has been reported.
Gastrointestinal side effects most commonly include nausea, vomiting and diarrhea. Clostridium difficile colitis has also been reported with oral neomycin (the active ingredient contained in Neo-Tab) therapy.
More Neo-Tab resources
- Neo-Tab Concise Consumer Information (Cerner Multum)
- neomycin MedFacts Consumer Leaflet (Wolters Kluwer)
- Neo-Fradin Prescribing Information (FDA)
- Neo-Fradin Advanced Consumer (Micromedex) - Includes Dosage Information
- Neo-Fradin solution MedFacts Consumer Leaflet (Wolters Kluwer)
- Neomycin Sulfate Monograph (AHFS DI)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.